-
The main types of cardiac amyloidosis are light chain amyloidosis and transthyretin amyloidosis.
-
Cardiac amyloidosis should be considered in patients with:
-
heart failure with preserved ejection fraction;
-
unexplained left ventricular hypertrophy;
-
heart failure refractory to conventional therapy.
-
-
Early diagnosis and therefore increased awareness is necessary to improve outcome.
Introduction
Type | Precursor Protein | Underlying disorder | Organ involvement | Sex and age (yrs.) | Typical clinical presentation |
---|---|---|---|---|---|
AL | Immunoglobin light chains | Plasma cell dyscrasias | Kidney Heart Liver ANS, PNS | Either sex, >50 | Heart failure with multi-organ involvement including nephrotic syndrome, autonomic dysfunction (orthostatic hypotension, diarrhoea, bladder disorder), peripheral neuropathy, macroglossia and periorbital purpura. Severe hypotension after ACEi/ARB |
ATTRwt (‘SSA’) | Wild-type transthyretin | Ageing | Heart | Male > Female >70 | Slowly progressive energy decline, exercise intolerance, weight loss and gastro-intestinal complaints. Left and right sided congestive heart failure with normal systolic function and clear diastolic dysfunction, arrythmias. History of CTS |
ATTRm | Mutant transthyretin | TTR gene mutation | Nervous systema Heart | Male > Female >40b | Slowly progressive heart failure symptoms (as in ATTRwt) with (invalidating) peripheral or autonomic neuropathy. Family history of neurological disease |
Diagnostic | Red flag |
---|---|
History taking | Carpal tunnel syndrome (bilateral) in an elderly patient with increased wall thickness on echocardiography, family history of neuropathy or SCD; Complaints of sensory peripheral neuropathy, foamy urine and or bleeding |
ECG | Low QRS voltage or disproportionally low voltage in the presence of increased left ventricular wall thickness/LVH |
ECG | Pseudo-infarct pattern in the absence of wall motion abnormalities on echocardiography |
Echocardiography | Symmetrical LVH (and RVH) in the absence of aortic stenosis or longstanding hypertension |
Echocardiography | Preserved LVEF, but reduced GLS with apical sparing (see also Fig. 1) |
CMR | Transmural or subendocardial LGE not related to a coronary artery territory, diffuse atrial LGE, RV LGE, suboptimal nulling |
CMR | Increased native T1 values, increased extracellular volume, myocardial oedema (T2) |
Laboratory testing | Disproportionally high level of NT-proBNP, chronically elevated troponin at low level with normal CAG |
Clinical situation | Medication | Comment |
---|---|---|
Fluid retention, oedema and orthopnoea | Loop diuretic, often combined with mineralocorticoid receptor antagonist (MRA) | Careful titration, avoid underfilling |
Supraventricular arrhythmias (atrial fibrillation/flutter) | β-blocker | Only in case of very high heart rate; generally to be avoided due to rate-dependent maintenance of cardiac output in advanced stage |
Amiodaron | Generally well tolerated. Capable of keeping sinus rhythm | |
Non-dihydropyridine calcium channel blockers (i.e. verapamil, diltiazem) | Contra-indicated as toxicity may occur quickly due to abnormal binding to amyloid fibrils; Same effect as with β‑blocker | |
Digoxin | Contra-indicated as toxicity may occur quickly due to abnormal binding to amyloid fibrils | |
Anticoagulant therapy | Should be considered even in sinus rhythm or low CHA2DS2VASC score due to a high risk of atrial thrombus in case of atrial dysfunction | |
QT-prolonging medication | Especially antipsychotics (haloperidol, quetiapine, olanzapine), tricyclic antidepressants (amitriptyline, nortriptyline, citalopram), anti-emetics (metoclopramide, ondansetron), antibiotics (ciproxin, azoles)a | Should be used with careful monitoring of QRS duration |